Allen J Lehman
Overview
Explore the profile of Allen J Lehman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bessette L, Rahman P, Kelsall J, Purvis J, Rampakakis E, Lehman A, et al.
J Rheumatol
. 2023 Jun;
50(9):1121-1126.
PMID: 37263649
Objective: To characterize the long-term incidence of infection in patients with rheumatoid arthritis (RA) treated with subcutaneous golimumab (GOL) in Canadian routine care, assess the effect of infections on GOL...
2.
Maksymowych W, Inman R, Bessette L, Rahman P, Rampakakis E, Asin-Milan O, et al.
Arthritis Res Ther
. 2023 Apr;
25(1):70.
PMID: 37118833
Objectives: To (i) determine whether sustained disease activity states, as measured by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS), impact function, and (ii)...
3.
Nantel F, Ling J, Rachich M, Asin-Milan O, Millson B, Golden S, et al.
Rheumatol Ther
. 2022 Aug;
9(5):1399-1420.
PMID: 36045308
Introduction: This retrospective, observational study aimed to analyze and assess adherence, persistence, dosing, and use of concomitant medications of seven self-administered target drugs (abatacept, golimumab, secukinumab, tocilizumab, ustekinumab, apremilast, and...
4.
Rahman P, Starr M, Haaland D, Bessette L, Teo M, Rampakakis E, et al.
BMC Rheumatol
. 2020 Dec;
4(1):56.
PMID: 33292797
Background: The objectives of this study were to describe the profile of ankylosing spondylitis (AS) patients treated with either infliximab (IFX) or subcutaneous golimumab (GLM) treatment in Canadian routine care...
5.
Rahman P, Baer P, Keystone E, Choquette D, Thorne C, Haraoui B, et al.
BMC Rheumatol
. 2020 Sep;
4:46.
PMID: 32968710
Background: Long-term clinical registries are essential tools to evaluate new therapies in a patient population that differs from those in randomized clinical trials. The objectives are to describe the profile...
6.
Rahman P, Arendse R, Khraishi M, Sholter D, Sheriff M, Rampakakis E, et al.
BMJ Open
. 2020 Aug;
10(8):e036245.
PMID: 32792436
Objectives: The objectives of this study were to describe the demographic profile and baseline disease characteristics of patients with psoriatic arthritis (PsA) treated with either infliximab (IFX), subcutaneous golimumab (GLM)...
7.
Coates L, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman A, et al.
Rheumatology (Oxford)
. 2018 Dec;
58(3):522-526.
PMID: 30517715
Objectives: Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed...
8.
Rahman P, Zummer M, Bessette L, Baer P, Haraoui B, Chow A, et al.
BMJ Open
. 2017 Sep;
7(8):e016619.
PMID: 28855200
Objective: To describe the minimal disease activity (MDA) rate over time in patients with psoriatic arthritis (PsA) receiving antitumour necrosis factor agents, evaluate prognostic factors of MDA achievement and identify...
9.
Rahman P, Choquette D, Bensen W, Khraishi M, Chow A, Zummer M, et al.
BMJ Open
. 2016 Apr;
6(4):e009661.
PMID: 27048632
Objectives: To describe the profile of patients with ankylosing spondylitis (AS) treated with infliximab in Canadian routine care and to assess the effectiveness and safety of infliximab in real world....
10.
Haraoui B, Jovaisas A, Bensen W, Faraawi R, Kelsall J, Dixit S, et al.
RMD Open
. 2015 Oct;
1(1):e000078.
PMID: 26509071
Objective: To describe the rate of concomitant oral corticosteroid use at antitumour necrosis factor (TNF) initiation and at disease remission, and to assess its effect on incidence of infection and...